Trial reportObesity research & clinical practice
Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study.
Trial report in Obesity research & clinical practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06243536. Cited by 42 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients
Who cites it
42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review.Brain and behavior · 2025Pooled it
- The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.Eating and weight disorders : EWD · 2025Pooled it
- Disordered Eating among People with Schizophrenia Spectrum Disorders: A Systematic Review.Nutrients · 2021Pooled it
- Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials.BMC endocrine disorders · 2019 · on this mapPooled it
- Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction.Biomedicines · 2026Review
- Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure.International journal of molecular sciences · 2026Review
- The Multifaceted Nature of GLP-1: Molecular Mechanisms and Signaling Pathways in Metabolic and Neurodegenerative Diseases.International journal of molecular sciences · 2026Review
- Beyond Weight Loss: Holistic Impacts of a Digital Weight Management Programme Integrating Tirzepatide.Cureus · 2026Article
- Pharmacological management of binge eating disorder.The mental health clinician · 2025Article
- GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis.Journal of the Endocrine Society · 2025Review
- Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review.International journal of molecular sciences · 2025Review
- GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Review
- Very low-calorie ketogenic diet and liraglutide as a synergistic strategy for the treatment of obesity: A short-term, non-randomised, observational, real-world clinical evaluation.Diabetes, obesity & metabolism · 2025Article
- Examining the Omission of Dietary Quality Data in Glucagon-Like Peptide 1 Clinical Trials: A Scoping Review.Advances in nutrition (Bethesda, Md.) · 2025Article
- Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights.Medical sciences (Basel, Switzerland) · 2025Review
- Novel potential pharmacological approaches in treating eating disorders comorbid with substance use disorders.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Test of a biobehavioral model linking weight suppression to binge-eating severity via leptin and glucagon-like peptide 1 in bulimia nervosa and related syndromes in women.Psychological medicine · 2025Article
- [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]Der Nervenarzt · 2025Review
- A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists.Acta diabetologica · 2025Article
- [Pharmacotherapy of eating disorders-An update].Der Nervenarzt · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined the effects of liraglutide, a glucagon-like peptide-1 analogue on appetite and plasma ghrelin in non-diabetic obese participants with subclinical binge eating (BE). Forty-four obese BE participants (mean age: 34±9 years, BMI: 35.9±4.2kg/m(2)) were randomly assigned to intervention or control groups for 12 weeks. All participants received standard advice for diet and exercise. Binge eating score, ghrelin levels and other anthropometric variables were evaluated at baseline and at the end of the study. Participants who received liraglutide showed significant improvement in binge eating, accompanied by reduction in body weight, BMI, waist circumference, systolic blood pressure, fasting glucose and total cholesterol. Ghrelin levels were significantly increased which may potentially diminish the weight loss effects of liraglutide beyond the intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.